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As a hallmark of tumor cells, metabolic alterations play a critical role in tumor development and could be targeted
for tumor therapy. Tumor suppressor p53 plays a central role in tumor prevention. As a transcription factor, p53
mainly exerts its function in tumor suppression through its transcriptional regulation of its target genes to initiate
various cellular responses. Cell cycle arrest, apoptosis and senescence are most well-understood functions of p53,
and are traditionally accepted as the major mechanisms for p53 in tumor suppression. Recent studies have revealed
a novel function of p53 in regulation of cellular metabolism. p53 regulates mitochondrial oxidative phosphorylation,
glycolysis, glutamine metabolism, lipid metabolism, and antioxidant defense. Through the regulation of these
metabolic processes, p53 maintains the homeostasis of cellular metabolism and redox balance in cells, which
contributes significantly to the role of p53 as a tumor suppressor. Further understanding of the role and molecular
mechanism of p53 in cellular metabolism could lead to the identification of novel targets and development of
novel strategies for tumor therapy.
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Tumor suppressor p53 plays a central role in tumor pre-
vention [1-4]. p53 is the most frequently-mutated gene in
human tumors; DNA mutations in p53 occur in over 50%
of all tumors and almost every type of tumor. Further-
more, it was estimated that p53 signaling is dysfunctional
in over 80% of tumors through different mechanisms in
addition to p53 mutations [1-5]. For instance, the negative
regulators of p53, including MDM2, Pirh2, Cop1, and
MDM4, are frequently amplified and/or overexpressed in
many tumors, which leads to the dysfunction of p53 sig-
naling [2,6-8]. In cervical cancer with a low mutation rate
of p53, p53 is often inactivated and degraded by human
papillomavirus E6 protein (HPV-E6) [9]. Disruption of
normal p53 function is often a prerequisite for the initi-
ation and/or progression of tumors. In mice, p53 knock-
out leads to the early development of various tumors,
including lymphoma and sarcoma [10,11]. In human
beings, Li–Fraumeni syndrome is a rare disease caused by* Correspondence: fengzh@umdnj.edu
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reproduction in any medium, provided the orthe germline mutations of p53. Li–Fraumeni syndrome
patients, who carry a germline heterozygous p53 gene, dis-
play a 50% cancer incidence by the age of 30 [12].
As a transcription factor, p53 mainly exerts its function
in tumor suppression through transcriptional regulation
of its target genes [1-4]. In response to a wide variety of
intracellular and extracellular stress signals, including
DNA damage, hypoxia, nutritional depletion and onco-
gene activation, p53 is activated primarily through post-
translational modifications, which leads to the increase of
p53 protein half-life and therefore p53 protein accumula-
tion in cells. The activated p53 protein then binds to a
specific DNA sequence, termed the p53-responsive elem-
ent, in its target genes to regulate their expression to
start various cellular responses. Through these cellular
responses, p53 facilitates DNA repair and inhibits the pro-
liferation of cells that could potentially become cancerous.
To date, over a hundred of p53 target genes have been
identified [13]. Regulating cell cycle arrest, senescence and
apoptosis are most well-understood functions of p53,
which have been accepted as the main mechanisms for
p53 to function as a tumor suppressor. Interestingly, re-
cent studies have revealed that p53 regulates cellulartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Liang et al. Cell & Bioscience 2013, 3:9 Page 2 of 10
http://www.cellandbioscience.com/content/3/1/9energy metabolism [14-17], and antioxidant defense
[18,19], which contribute greatly to the role of p53 in
tumor suppression. This concept is supported by emer-
ging evidence, including evidence from mouse models.
For instance, a recent study showed that while p53
deficiency results in the elevated intracellular reactive
oxygen species (ROS) levels, DNA oxidation and muta-
tions in cells, dietary supplementation with antioxidant N-
acetylcysteine substantially improves karyotype stability
and prevents the early-onset tumors in p53 null mice [19].
In another most recent study, mice bearing lysine to argin-
ine mutations at three (p53(3KR); K117R+K161R+K162R)
of p53 acetylation sites were generated. p53(3KR/3KR)
cells display impaired p53-mediated cell-cycle arrest, sen-
escence and apoptosis. Unlike p53 null mice, which rap-
idly succumb to lymphomas, p53(3KR/3KR) mice did not
develop early-onset lymphomas. Notably, p53(3KR/3KR)
cells retain the ability to regulate energy metabolism and
ROS production [20]. These results strongly suggest that
unconventional activities of p53, such as metabolic regula-
tion and antioxidant function, could be critical for tumor
suppression.
Metabolic alterations in cancer
The Warburg effect is the best characterized metabolic
phenotype observed in tumor cells. In 1926, Otto
Warburg found that unlike majority of normal cells
which depends on mitochondrial oxidative phosphoryl-
ation to provide energy, most tumor cells primarily
utilize glycolysis for their energy needs even under nor-
mal oxygen concentrations, a phenomenon termed “the
Warburg effect” [21]. Compared with mitochondrial oxi-
dative phosphorylation, which produces 36 ATP per glu-
cose molecule, aerobic glycolysis is a much less efficient
ATP-generating pathway, which only produces 2 ATP
per glucose molecule. As a result, tumor cells have a
much higher rate of glucose uptake and utilization than
normal cells, and produce a large amount of lactate.
Warburg originally hypothesized that tumor cells have a
defect in mitochondrial oxidative phosphorylation which
drives cells to rely on aerobic glycolysis for their energy
needs. However, subsequent studies found that most
tumor cells display a normal mitochondrial function, in-
cluding normal capacity for mitochondrial oxidative
phosphorylation. The biological significance of the War-
burg effect in tumor development had been elusive for
many decades since its discovery. It was unclear whether
the Warburg effect contributes to tumorigenesis or was
simply a by-product of tumorigenesis. Furthermore, the
underlying mechanism for the Warburg effect was un-
clear. Nevertheless, the Warburg effect provides a base
for Positron Emission Tomography imaging, which has
been developed for tumor detecting since tumors take
up more of the glucose analog 18flurodeoxyglucose thannormal tissues. Remarkably, recent research has begun to
answer these questions. These studies have led to the con-
cept that the metabolic alterations are a hallmark of tumor
cells [22-24]. Compelling evidence has shown that cancer
cells depend upon metabolic alterations for continued
growth, proliferation and survival [16,23-25]. To support
the needs for the rapid growth and proliferation of cancer
cells, cancer cells acquire following metabolic alterations:
rapid energy generation, enhanced biosynthesis of macro-
molecules (including carbohydrates, proteins, lipids, and
nucleic acids), and maintenance of appropriate cellular
redox status. The enhanced aerobic glycolysis (the
Warburg effect) not only provides a rapid ATP generation,
but also provides a biosynthetic advantage and contributes
to a proper control of redox balance for tumor cells, which
confers tumor cells advantages of proliferation and sur-
vival [16,23-25]. Reversing the Warburg effect in tumor
cells has been shown to greatly compromise the tumori-
genicity of cancer cells [26,27], which suggests that target-
ing the metabolic changes could be an effective strategy
for cancer treatment.
In addition to the Warburg effect, tumors show altera-
tions in many other aspects of metabolism, including
altered metabolism of amino acids and lipid. For in-
stance, many tumors are addicted to glutamine, which is
a non-essential amino acid for human beings [28-30].
Glutamine can be used for synthesis of proteins and
nucleotides, and ATP generation for rapidly growing
cancer cells. Glutamine can be converted into glutamate
by glutaminase, which can be further converted into α-
ketoglutarate, an important substrate for the tricarbox-
yclic acid (TCA) cycle to produce ATP in cells, a process
named glutaminolysis. Furthermore, many tumor cells
show high rates of de novo lipid synthesis [31-34]. Lipids
have been reported to promote different aspects of can-
cer development, including promoting the growth, pro-
liferation, and survival of tumor cells, and maintaining
redox balance [31].
Regulation of cancer metabolism by oncogenes and tumor
suppressors
Recent studies have begun to reveal underlying molecu-
lar mechanisms for the altered metabolism in cancer.
The activation of oncogenes (such as Myc, HIF-1α, and
PI3K/Akt) and inactivation of tumor suppressors (such
as p53, PTEN, TSC2 and LKB1) in cancer cells have been
shown to contribute to metabolic alterations in cancer
[23-25,35]. Myc promotes glucose uptake through the up-
regulation of glucose transporter 1 (GLUT1), and stimu-
lates glycolysis through transcriptional up-regulation
of many glycolytic enzymes, including lactate dehydrogen-
ase A (LDHA), hexokinase 2 and phosphofructokinase
[36]. In addition to promoting glycolysis, Myc also
activates glutaminolysis [30,37]. Myc transcriptionally
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to promote glutamine uptake in cells. Furthermore, Myc
induces the expression of glutaminase 1 (GLS1), an en-
zyme that converts glutamine into glutamate as the first
rate-limiting enzyme of glutaminolysis, by negative
regulation of the expression of miR-23a and miR-23b,
microRNAs that repress GLS1 expression [37]. HIF-1α
activation and stabilization in tumors also contributes
greatly to the enhanced glycolysis. HIF-1α stimulates
glycolysis through direct transactivation of glucose
transporters (such as GLUT1) and many glycolytic
enzymes (such as pyruvate dehydrogenase kinase 1
(PDK1) and pyruvate kinase type M2 (PKM2)) [36,38].
PDK1 is a kinase that phsphorylates and inhibits pyru-
vate dehydrogenase, which converts pyruvate into
acetyl-CoA for TCA cycle. The induction of PDK1 by
HIF-1α slows the conversion of pyruvate into acetyl-
CoA and prevents the entry of pyruvate into the TCA
cycle [39,40]. PKM2 is a fetal isoform of pyruvate kin-
ase, which is highly expressed in many tumors. Interest-
ingly, PKM2 is ineffective at promoting glycolysis
compared with other pyruvate kinase isoforms, such as
PKM1 which is expressed in the muscle and brain
[41,42]. By slowing glycolysis, PKM2 results in a buildup
of carbohydrate metabolites in cells that can be used to
generate macromolecules to support the rapid growth
and proliferation of tumor cells. In addition to Myc and
HIF-1α, activation of PI3K/AKT signaling pathway also
plays a critical role in activating glycolysis. AKT induces
the translocation of glucose transporters, GLUT1 and
GLUT4, to cell surface to promote glucose uptake [43].
AKT also activates glycolytic enzymes, such as hexoki-
nase 2 and phosphofructokinase 1 and 2. Furthermore,
AKT phosphorylates and inactivates tumor suppressor
TSC2, a negative regulator of mTOR, to promote gly-
colysis [44]. The mTOR signaling pathway plays a crit-
ical role in tumorigenesis and metabolism [17,45].
Activation of mTOR has been reported to induce HIF-
1α, which in turn induces PKM2 expression to promote
glycolysis [46].
In addition to the activation of oncogenes, inactivation
of tumor suppressors has been recently shown to lead to
the metabolic alterations in cancer. For instance, PTEN
can inhibit glycolysis as well as glutaminolysis through
both PI3K/AKT-dependent and -independent pathways
[47]. TSC2 inhibits glycolysis through its negative regu-
lation of mTOR. LKB1 negatively regulates glycolysis
through its activation of AMP-activated protein kinase
(AMPK), which activates TSC2 to negatively regulate the
activity of mTOR [48]. Recent studies have shown that
p53 plays an important role in regulation of cellular me-
tabolism, including mitochondrial oxidative phosphoryl-
ation, glycolysis, glutaminolysis, and fatty acid oxidation.
Considering that p53 is mutated in over 50% of humancancer and dysfunctional in more cancer, loss of p53
function should be an important mechanism contribut-
ing to the metabolic alterations in cancer.
p53 regulates mitochondrial oxidative phosphorylation
and glycolysis
p53 plays a critical role in maintaining the integrity of
mitochondria and oxidative phosphorylation and down-
regulation of glycolysis (Figure 1). Loss of p53 results in
the deficiency of mitochondrial oxidative phosphorylation
and enhanced glycolysis in both cultured cells and mouse
models [14]. Several p53 target genes have been identified
to mediate the role of p53 in maintaining mitochondrial
oxidative phosphorylation, including SCO2 (synthesis of
cytochrome c oxidase 2), AIF (apotosis-inducing factor),
GLS2 (glutaminase 2), Parkin and p53R2. The SCO2 is a
key regulator of the cytochrome c oxidase complex (mito-
chondrial complex IV) that is essential for mitochondrial
oxidative phosphorylation. p53 induces the expression of
SCO2 to ensure the maintenance of the cytochrome c oxi-
dase complex, thereby enhancing oxidative phosphoryl-
ation [14]. AIF is required to maintain the integrity of
mitochondrial complex I in the mitochondrial electron
transport chain. p53 transcriptionally induces AIF to pro-
mote mitochondrial oxidative phosphorylation [49,50].
GLS2 is a mitochondrial glutaminase that catalyzes the hy-
drolysis of glutamine to glutamate. p53 increases GLS2 ex-
pression, which enhances the production of glutamate and
a-ketoglutarate in cells, and thereby promotes mitochon-
drial oxidative phosphorylation and ATP generation
[51,52]. Parkin was recently reported to contribute to the
function of p53 in regulating oxidative phosphorylation
[53]. Parkin is a gene associated with Parkinson disease,
one of the most common neurodegenerative diseases.
Mutations of the Parkin gene account for most autosomal
recessive forms of juvenile Parkinson disease. Parkin has
been recently shown to be a potential tumor suppressor.
Diminished expression and mutations of the Parkin gene
have been frequently observed in various tumors [54,55].
Parkin deficiency results in reduced mitochondrial oxida-
tive phosphorylation [53]. Furthermore, Parkin increases
the protein expression of pyruvate dehydrogenase E1α1
(PDHA1). PDHA1 is a critical component of the pyruvate
dehydrogenase (PDH) complex, which catalyzes the con-
version of pyruvate into acetyl-CoA, a primary substrate
for TCA cycle, and serves as a critical link between gly-
colysis and oxidative phosphorylation. Parkin deficiency
reduces the levels of PDHA1 protein, leading to the
decreased levels of acetyl-CoA, which contributes to the
impaired oxidative phosphorylation and enhanced glycoly-
sis in cells [53]. p53 also activates PDH through its tran-
scriptional repression of pyruvate dehydrogenase kinase-2
(PDK2), which inhibits PDH by phosphorylation of












































Figure 1 The regulation of cellular metabolism by p53. p53 regulates mitochondrial oxidative phosphorylation, glycolysis, glutaminolysis and
fatty acid oxidation in cells. p53 transcriptionally induces SCO2, AIF and p53R2, and physically interacts with mtDNA Poly γ to maintain the
mitochondrial integrity and promotes oxidative phosphorylation. p53 reduces glucose uptake through direct repression of the transcription of
GLUT 1 & 4, and indirect repression of the expression of GLUT 3. p53 negatively regulates PGM at the protein level and transcriptionally induces
TIGAR and Parkin to inhibit glycolysis. Parkin positively regulates PDH, which converts pyruvate into acetyl-CoA. p53 negatively regulates the
expression of PDK2, which phosphorylates and inhibits the PDH activity. p53 induces the expression of GLS2, which catalyzes the hydrolysis of
glutamine to glutamate. The latter can be further converted into α-KG (α-ketoglutarate). By increasing the levels of α-KG, GLS2 promotes TCA
cycle and oxidative phosphorylation. p53 physically interacts with G6PD to negatively regulate the activity of G6PD, and thereby down-regulates
PPP (pentose phosphate pathway), a pathway critical for nucleotide synthesis and NADPH production. p53 induces the expression of GAMT and
Lipin1 to promote fatty acid oxidation. By producing acetyl-CoA, fatty acid oxidation contributes to the maintenance of TCA cycle and
mitochondrial oxidative phosphorylation.
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instead of lactate, and promotes the mitochondrial oxida-
tive phosphorylation and represses the glycolysis in cells.
Ribonucleotide reductase subunit p53R2 plays an import-
ant role in the maintenance of mitochondrial DNA
(mtDNA). Loss of p53R2 results in decreased mtDNA and
mitochondrial function in cells. Through the transcrip-
tional up-regulation of p53R2, p53 maintains the integrity
of mtDNA and mitochondrial oxidative phosphorylation
[57,58]. In addition to the transcriptional regulation of its
target genes, p53 also maintains mitochondrial genetic sta-
bility through its interaction with mtDNA polymerase γ
(mtDNA Poly γ) in response to mtDNA damage induced
by intracellular and extracellular stress, including ROS.
p53 protein physically interacts with mtDNA Poly γ to en-
hance DNA replication function of Poly γ and therefore
mitochondrial function. Loss of p53 results in a significant
increase in mtDNA vulnerability to damage, leading to
increased frequency of mtDNA mutations [59]. These
findings together provide strong evidence that p53 plays acritical role in maintaining mitochondrial integrity and
promoting mitochondrial oxidative phosphorylation.
In addition to promoting mitochondrial oxidative phos-
phorylation, p53 represses aerobic glycolysis through regu-
lating glucose transporters and glycolytic enzymes
(Figure 1). p53 reduces glucose uptake through direct re-
pression of the expression of glucose transporters 1 & 4
(GLUT1 and GLUT4) [60], and indirect repression of the
expression of glucose transporter 3 (GLUT3) [61]. The lat-
ter occurs through the negative regulation of NF-κB sig-
naling by p53. p53 reduces the activity of NF-κB signaling
by inhibiting the activities of IκB kinase α and β, which in
turn reduces the expression of GLUT3 [61]. p53 also regu-
lates the enzymes involved in glycolysis, such as PGM
(phosphoglycerate mutase) and TIGAR (TP53-induced
glycolysis and apoptosis regulator). PGM acts at the later
stage of glycolytic pathway. p53 promotes the ubiquitia-
tion and degradation of PGM protein. Loss of p53 results
in the increased PGM expression, thereby enhancing gly-
colysis [62]. TIGAR is another target of p53 which
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tions as an enzyme that dephosphorylates fructose-2,6-
bisphosphate to fructose-6-phosphate. This activity of
TIGAR counteracts that of phosphofructokinase, a key
regulatory enzyme in glycolysis. By lowering the intracellu-
lar levels of fructose-2,6-bisphosphate, TIGAR reduces
glycolysis and diverts glucose catabolism to the pentose
phosphate pathway (PPP). Parkin also contributes to the
function of p53 in negative regulation of glycolysis. Parkin
deficiency promotes glycolysis, whereas ectopic expression
of Parkin reduces glycolysis in tumor cells [53]. Currently,
it is still unclear whether Parkin can directly repress gly-
colysis or whether the enhanced glycolysis resulted from
Parkin deficiency is simply due to the impaired mitochon-
drial oxidative phosphorylation.
p53 can inhibit the pentose phosphate pathway to fur-
ther regulates glucose metabolism in cells (Figure 1) [63].
The pentose phosphate pathway is important for both glu-
cose metabolism and biosynthesis in cancer cells. In an
oxidative phase, the pentose phosphate pathway generates
reduced NADPH, an important intracellular reductant
required for reductive biosynthesis such as ribose 5-phos-
phate, the precursor for biosynthesis of nucleotides. This
is followed by a non-oxidative interconversion of ribose 5-
phosphate to the intermediates in the glycolytic pathway.
p53 protein directly binds to glucose-6-phosphate de-
hydrogenase (G6PD), the first and rate-limiting enzyme in
the pentose phosphate pathway, and prevents the forma-
tion of active G6PD dimmer [63]. Through the inhibition
of pentose phosphate pathway, p53 suppresses glucose
metabolism and biosynthesis. Loss of p53 results in
enhanced pentose phosphate pathway, which in turn
increases glucose uptake and directs glucose towards bio-
synthesis in tumor cells.
p53 can further regulate glycolysis through its regula-
tion of PI3K/AKT and mTOR signaling pathways
(Figure 2). The aberrant activation of these two pathways
has been frequently observed in various tumors, which
plays an important role in stimulating glycolysis and
promoting growth and proliferation of tumor cells
[24,64,65]. p53 negatively regulates these two pathways
through inducing a group of target genes that act as
negative regulators of these two pathways [17,66,67].
p53 induces IGF-BP3 (insulin-like growth factor binding
protein 3), which binds to IGF1 and prevents its binding
to IGF receptor, resulting in the down-regulation of the
PI3K/AKT signaling. p53 also induces PTEN to nega-
tively regulate the PI3K/AKT signaling [68,69]. As a lipid
phosphatase, PTEN dephosphorylates phosphatidylinosi-
tol 3,4,5-trisphosphate (PIP3), the second messenger
produced by PI3K, and thereby inhibits the PI3K/AKT
signaling pathway. AMPK is a major upstream negative
regulator of mTOR. p53 activates AMPK through its in-
duction of AMPK-β and Sestrins 1/2, leading to thedown-regulation of the mTOR activity [69,70]. p53 also
induces TSC2 to negatively regulate the mTOR activity.
Furthermore, p53 induces the expression of REDD1,
which inhibits the mTOR activity by releasing TSC2
from the association with inhibitory 14-3-3 proteins in
response to hypoxia [69,71,72]. Through the regulation
of multiple p53 targets in the PI3K/AKT and AMPK/
mTOR pathways, p53 negatively regulates the activities
of these two pathways, which in turn leads to inhibition
of glycolysis in cells. In summary, through the regulation
of many different p53 target genes and several different
pathways, p53 promotes mitochondrial oxidative phos-
phorylation and inhibits aerobic glycolysis, leading to the
negative regulation of the Warburg effect.
p53 regulates glutaminolysis and lipid metabolism
In addition to glucose metabolism, p53 regulates many
other aspects of cellular metabolism, including glutamino-
lysis and fatty acid oxidation (Figure 1). GLS2 acts as a
mediator of p53's role in glutaminolysis [51]. p53 increases
the expression of GLS2, which in turn increases the pro-
duction of glutamate and α-ketoglutarate in cells, leading
to the enhanced mitochondrial oxidative phosphorylation
and ATP generation. At the same time, GLS2 increases
the levels of antioxidant glutathione (GSH) in cells
through increasing the levels of intracellular glutamate, a
precursor for GSH, thereby lowering the ROS levels in
cells. It has been reported that GLS2 levels are signifi-
cantly decreased in liver and brain tumors [51,52,73]. Ec-
topic expression of GLS2 in tumor cells significantly
reduced tumorigenicity [51,52,73]. These results strongly
suggest a potential role of GLS2 in tumor suppression.
Interestingly, GLS2 shares a considerable degree of se-
quence similarity with GLS1. It was reported that the ex-
pression of GLS1 can be induced by Myc, which in turn
promotes the proliferation of lymphoma and prostate
tumor cells [37]. It is still unclear why GLS1 and GLS2
have contrasting roles in tumorigenesis, and furthermore,
the mechanism for GLS2 in tumor suppression remains
unclear [51].
Emerging evidence also shows that p53 is involved in
lipid metabolism. In response to nutritional starvation,
p53 induces fatty acid oxidation to drive the TCA cycle
to provide energy for cells (Figure 1). Guanidinoacetate
methyltransferase (GAMT) is a critical enzyme that
synthesizes creatine. The creatine-phosphocreatine sys-
tem plays an essential role in energy storage and trans-
mission by re-synthesizing ATP. This system provides a
quick source of energy for cells or tissues with high-
energy demands, such as muscle and brain. GAMT was
identified as a p53 target gene that plays as a key down-
stream effector of adaptive response to nutritional stress
[74]. In response to glucose starvation, GAMT is

















Figure 2 p53 negatively regulates the PI3K/AKT and mTOR pathways to down-regulate glycolysis. The PI3K/AKT and mTOR pathways play
critical roles in stimulating glycolysis in tumors. p53 negatively regulates the PI3K/AKT signaling through inducing the expression of IGF-BP3 and
PTEN. p53 also negatively regulates mTOR activity through inducing the expression of AMPK-β, Sestrins 1/2, TSC2 and REDD1.
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reduces glucose starvation-induced apoptosis in cells,
which suggests that GAMT induction by p53 provides
energy for p53-mediated apoptosis in response to glu-
cose starvation. Lipin1 was recently identified as another
p53-regualted gene that mediates the role of p53 in fatty
acid oxidation [75]. Lipin1 is essential for normal adi-
pose tissue development and is also an important regula-
tor of fatty acid metabolism [76,77]. As a nuclear
transcriptional coactivator, Lipin1 interacts with a com-
plex containing peroxisome proliferator-activated recep-
tor (PPAR) α and PPAR γ coactivator-1α (PGC-1α) to
regulate the expression of genes involved in fatty acid
oxidation. As a phosphatidate phosphatase enzyme,
Lipin1 catalyzes the conversion of phosphatidate to dia-
cylglycerol. Lipin1 is induced by p53 in response to glu-
cose starvation, which in turn results in the up-
regulation of fatty acid oxidation [75]. Therefore, GAMT
and Lipin1 connect p53 to fatty acid oxidation in re-
sponse to nutritional stress. By converting acyl-CoA to
acetyl-CoA, fatty acid oxidation connects to TCA cycle
and contributes to the maintenance of mitochondrial
oxidative phosphorylation. Therefore, the regulation of
fatty acid oxidation by p53 could also contribute to the
function of p53 in maintaining mitochondrial oxidative
phosphorylation and repressing glycolysis in cells.
p53 regulates antioxidant defense
Oxidative stress and increased levels of ROS in cells play
an important role in tumorigenesis. Recent studies have
shown that reducing the ROS levels and enhancing anti-
oxidant defense is an important mechanism of p53 intumor suppression. Mitochondrial oxidative phosphoryl-
ation is a main source of endogenous ROS in cells.
Whereas p53 promotes mitochondrial oxidative phos-
phorylation to maintain the homeostasis of cellular en-
ergy metabolism, p53 also plays a fundamental role in
reducing the intracellular ROS levels mainly resulted
from mitochondrial oxidative phosphorylation and
maintaining the redox balance. To exert its antioxidant
function, p53 induces a group of antioxidant genes, in-
cluding sestrins 1/2, TIGAR, GPX1, ALDH4, GLS2, and
Parkin, especially under conditions of nonstress or low
stress, to lower ROS levels and prevent DNA damage
(Figure 3) [15,18,51,53,78,79]. Sestrins are a family of
proteins required for regeneration of peroxiredoxins,
which are thiol-containing peroxidases and major reduc-
tants of peroxides in cells [18]. TIGAR diverts glucose
through the pentose phosphate pathway, increasing the
levels of antioxidant NADPH [15]. GPX1 is a primary
antioxidant enzyme that scavenges hydrogen pero-
xide or hydroperoxides in cells [78]. ALDH4 is a
NAD+ dependent enzyme in mitochondrial matrix,
which catalyzes proline degradation in mitochondria and
thereby reduces intracellular ROS levels [79]. By increas-
ing the intracellular levels of antioxidant GSH, both
GLS2 and Parkin can reduce ROS levels in cells [51-53].
In addition to the direct transcription regulation of anti-
oxidant genes, p53 also reduces ROS levels in cells by
promoting the stabilization of NRF2 through its up-
regulation of p21 [80]. As a transcription factor, NRF2
induces several antioxidant genes, and thus plays a crit-
ical role in antioxidant defense in cells. Under non-































Figure 3 The regulation of oxidative stress and ROS by p53. p53 exerts either antioxidant or prooxidant activity depending on extent of
stress signals. Under the conditions of nonstress or low stress, p53 induces antioxidant genes, such as sestrins 1/2, TIGAR, GPX1, ALDH4, GLS2 and
Parkin, to lower ROS levels in cells. Furthermore, p53 induces p21 to stabilize NRF2, a transcription factor which induces the expression of
antioxidant genes to lower ROS levels. This antioxidant activity protects cells from oxidative stress-induced DNA damage and mutations, and also
promotes cell survival. Under the conditions of severe stress, p53 induces prooxidant genes, including PIG3, PIG6, FDRX, Bax and Puma, to further
induce ROS levels in cells, which in turn further activates p53. This prooxidant activity leads to the p53-mediated apoptosis and senescence to
prevent the propagation of mutation-bearing cells. Thus, both antioxidant and prooxidant activities of p53 contribute to the role of p53 in
tumor suppression.
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degraded. In response to oxidative stress, the induction
of p21 by p53 inhibits the interaction between NRF2
and Keap1, leading to the increase of NRF2. Consistent
with the function of p53 in regulating genes involved in
antioxidant defense, p53 deficiency results in the eleva-
tion of intracellular ROS levels, which greatly increases
DNA oxidation and the rate of mutagenesis in cells.
These effects could be substantially reversed by ectopic
expression of antioxidant p53 target Sestrins in p53
null cells or by the application of antioxidant N-
acetylcysteine both in vitro and in vivo [18,19].
Interestingly, in addition to the function of antioxidant
defense, p53 can exert prooxidant function through
transcriptional up-regulation of a group of prooxidant
genes depending on the levels of oxidative stress that
cells are facing (Figure 3). In response to severe oxida-
tive stress, the intracellular levels of ROS are elevated,
which activate p53, leading to the p53-mediated apop-
tosis and senescence to eliminate cells damaged by oxi-
dative stress. At the same time, the activated p53 protein
induces the expression of prooxidant genes, including
PIG3, PIG6, FDXR, Bax, and Puma, all of which can fur-
ther increase intracellular ROS levels and promote the
p53-mediated apoptosis and senescence to maintain gen-
omic integrity [81-84].Conclusions
Here we reviewed our current understanding of the role
and mechanisms of p53 in maintaining the homeostasis
of cellular energy metabolism and the redox balance in
cells. Whereas cell-cycle arrest, apoptosis, and senes-
cence are traditionally accepted as the major mechan-
isms by which p53 exerts its tumor suppressive function,
these findings provide strong evidence that the functions
of p53 in maintaining the homeostasis of cellular energy
metabolism and the redox balance in cells contribute
significantly to the role of p53 as a tumor suppressor.
Metabolic alterations are a hallmark of cancer cells.
Ample evidence has shown that the metabolic altera-
tions are critical for the growth, proliferation and sur-
vival of tumor cells. Therapeutic strategies targeting
cancer metabolism are being developed and tested for
cancer treatment. For instance, Metformin, an anti-
diabetic drug, which regulates cell metabolism and the
AMPK/mTOR signaling, has been already selected as a
candidate for tumor therapy [85,86]. Recent studies have
shown that reactivation of p53 in tumors leads to the
tumor regression in animal models, which provide fur-
ther evidence that p53 can be targeted for cancer ther-
apy [87,88]. A number of small molecular drugs that
activate p53 have been developed, including Nutlins.
Nutlins interact with MDM2 to release p53 from the
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tion [89,90]. p53 is emerging as a key regulator of the
homeostasis of cellular metabolism; p53 regulates mito-
chondrial oxidative phosphorylation, glycolysis, glutami-
nolysis and fatty acid oxidation. However, it is still not
fully understood the roles and mechanisms of p53 in
regulation of different aspects of cellular metabolism,
and how the regulation of these different aspects of cel-
lular metabolism contributes to the function of p53 in
tumor suppression. A better understanding of the func-
tion of p53 and its target genes involved in the regula-
tion of cellular metabolism could lead to a better
understanding of tumorigenesis and identification of
new targets for tumor therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YL and JL prepared the initial draft of the paper. ZF modified and finalized
the paper. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Institutes of Health
(1R01CA143204-01) and New Jersey Commission on Cancer Research
(NJCCR) to Z.F. J.L. was supported by a NJCCR fellowship.
Received: 20 August 2012 Accepted: 6 December 2012
Published: 6 February 2013
References
1. Levine AJ, Hu W, Feng Z: The P53 pathway: what questions remain to be
explored? Cell Death Differ 2006, 13(6):1027–1036.
2. Vousden KH, Prives C: Blinded by the Light: The Growing Complexity of
p53. Cell 2009, 137(3):413–431.
3. Levine AJ, Oren M: The first 30 years of p53: growing ever more complex.
Nat Rev Cancer 2009, 9(10):749–758.
4. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000,
408(6810):307–310.
5. Olivier M, Hussain SP, Caron De Fromentel C, Hainaut P, Harris CC: TP53
mutation spectra and load: a tool for generating hypotheses on the
etiology of cancer. IARC Sci Publ 2004, 157:247–270.
6. Wade M, Wahl GM: Targeting Mdm2 and Mdmx in cancer therapy: better
living through medicinal chemistry? Mol Cancer Res 2009, 7(1):1–11.
7. Lu X: Tied up in loops: positive and negative autoregulation of p53. Cold
Spring Harb Perspect Biol 2010, 2(5):a000984.
8. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback
loops. Oncogene 2005, 24(17):2899–2908.
9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6
oncoprotein encoded by human papillomavirus types 16 and 18
promotes the degradation of p53. Cell 1990, 63(6):1129–1136.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel
JS, Bradley A: Mice deficient for p53 are developmentally normal but
susceptible to spontaneous tumours. Nature 1992, 356(6366):215–221.
11. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT,
Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol
1994, 4(1):1–7.
12. Strong LC: General keynote: hereditary cancer: lessons from Li-Fraumeni
syndrome. Gynecol Oncol 2003, 88(1 Pt 2):S4–S7. discussion S11-13.
13. Riley T, Sontag E, Chen P, Levine A: Transcriptional control of human
p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9(5):402–412.
14. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ,
Bunz F, Hwang PM: p53 regulates mitochondrial respiration. Science 2006,
312(5780):1650–1653.
15. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E,
Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis.
Cell 2006, 126(1):107–120.16. Vousden KH, Ryan KM: p53 and metabolism. Nat Rev Cancer 2009, 9(10):691–700.
17. Feng Z, Levine AJ: The regulation of energy metabolism and the IGF-1/
mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20(7):427–434.
18. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM:
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of
bacterial AhpD. Science 2004, 304(5670):596–600.
19. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE,
Chumakov PM: The antioxidant function of the p53 tumor suppressor.
Nat Med 2005, 11(12):1306–1313.
20. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W: Tumor
Suppression in the Absence of p53-Mediated Cell-Cycle Arrest,
Apoptosis, and Senescence. Cell 2012, 149(6):1269–1283.
21. Warburg O: On the origin of cancer cells. Science 1956, 123(3191):309–314.
22. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144(5):646–674.
23. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science
2009, 324(5930):1029–1033.
24. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev
Cancer 2011, 11(2):85–95.
25. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond.
Cell 2008, 134(5):703–707.
26. Fantin VR, St-Pierre J, Leder P: Attenuation of LDH-A expression uncovers
a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 2006, 9(6):425–434.
27. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE,
Wei R, Fleming MD, Schreiber SL, Cantley LC: The M2 splice isoform of
pyruvate kinase is important for cancer metabolism and tumour growth.
Nature 2008, 452(7184):230–233.
28. Dang CV: Glutaminolysis: supplying carbon or nitrogen or both for
cancer cells? Cell Cycle 2010, 9(19):3884–3886.
29. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF,
Ambrosio AL, Dias SM, Dang CV, et al: Targeting mitochondrial
glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010,
18(3):207–219.
30. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK,
Nissim I, Daikhin E, Yudkoff M, McMahon SB, et al: Myc regulates a
transcriptional program that stimulates mitochondrial glutaminolysis
and leads to glutamine addiction. Proc Natl Acad Sci USA 2008,
105(48):18782–18787.
31. Santos CR, Schulze A: Lipid metabolism in cancer. FEBS J 2012,
279(15):2610–2623.
32. Biswas S, Lunec J, Bartlett K: Non-glucose metabolism in cancer cells-is it
all in the fat? Cancer Metastasis Rev 2012, 31(3-4):689–698.
33. Medes G, Thomas A, Weinhouse S: Metabolism of neoplastic tissue. IV. A
study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res
1953, 13(1):27–29.
34. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack
GR: Fatty acid synthesis: a potential selective target for antineoplastic
therapy. Proc Natl Acad Sci USA 1994, 91(14):6379–6383.
35. Levine AJ, Puzio-Kuter AM: The control of the metabolic switch in cancers
by oncogenes and tumor suppressor genes. Science 2010,
330(6009):1340–1344.
36. Dang CV, Kim JW, Gao P, Yustein J: The interplay between MYC and HIF in
cancer. Nat Rev Cancer 2008, 8(1):51–56.
37. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo
AM, Van Eyk JE, Mendell JT, et al: c-Myc suppression of miR-23a/b
enhances mitochondrial glutaminase expression and glutamine
metabolism. Nature 2009, 458(7239):762–765.
38. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour.
Nat Rev Cancer 2008, 8(9):705–713.
39. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC: HIF-1 mediates
adaptation to hypoxia by actively downregulating mitochondrial oxygen
consumption. Cell Metab 2006, 3(3):187–197.
40. Kim JW, Tchernyshyov I, Semenza GL, Dang CV: HIF-1-mediated expression
of pyruvate dehydrogenase kinase: a metabolic switch required for
cellular adaptation to hypoxia. Cell Metab 2006, 3(3):177–185.
41. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P:
Modulation of type M2 pyruvate kinase activity by the human
papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 1999,
96(4):1291–1296.
Liang et al. Cell & Bioscience 2013, 3:9 Page 9 of 10
http://www.cellandbioscience.com/content/3/1/942. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC: Pyruvate
kinase M2 is a phosphotyrosine-binding protein. Nature 2008,
452(7184):181–186.
43. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR:
Phosphatidylinositol 3-kinase activation is required for insulin
stimulation of pp 70 S6 kinase, DNA synthesis, and glucose transporter
translocation. Mol Cell Biol 1994, 14(7):4902–4911.
44. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited
by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4(9):648–657.
45. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway
in human disease. Nat Genet 2005, 37(1):19–24.
46. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen
R, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase
isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.
Proc Natl Acad Sci USA 2011, 108(10):4129–4134.
47. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC,
Anastasiou D, Ito K, Sasaki AT, Rameh L, et al: Systemic elevation of PTEN
induces a tumor-suppressive metabolic state. Cell 2012, 149(1):49–62.
48. Shaw R, Kosmatka M, Bardeesy N, Hurley R, Witters L, DePinho R, Cantley L:
The tumor suppressor LKB1 kinase directly activates AMP-activated
kinase and regulates apoptosis in response to energy stress. Proc Natl
Acad Sci USA 2004, 101:3329–3335.
49. Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, Mastroberardino
PG, Pequignot MO, Casares N, Lazar V, et al: AIF deficiency compromises
oxidative phosphorylation. EMBO J 2004, 23(23):4679–4689.
50. Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V:
Regulation of AIF expression by p53. Cell Death Differ 2006, 13(12):2140–2149.
51. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z: Glutaminase 2, a novel
p53 target gene regulating energy metabolism and antioxidant function.
Proc Natl Acad Sci USA 2010, 107(16):7455–7460.
52. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin
M, Hosokawa H, Nakayama T, Suzuki Y, et al: Phosphate-activated
glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism
and reactive oxygen species. Proc Natl Acad Sci USA 2010, 107(16):7461–7466.
53. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, Hu W, Feng Z: Parkin, a
p53 target gene, mediates the role of p53 in glucose metabolism and
the Warburg effect. Proc Natl Acad Sci USA 2011, 108(39):16259–16264.
54. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F,
Drusco A, Shimizu M, Masciullo V, et al: Parkin, a gene implicated in
autosomal recessive juvenile parkinsonism, is a candidate tumor
suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003,
100(10):5956–5961.
55. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K,
Luo F, Cantley LC, Wyllie AH, Adams DJ, et al: PARK2 deletions occur
frequently in sporadic colorectal cancer and accelerate adenoma
development in Apc mutant mice. Proc Natl Acad Sci USA 2010, 107
(34):15145–15150.
56. Contractor T, Harris CR: p53 negatively regulates transcription of the
pyruvate dehydrogenase kinase Pdk2. Cancer Res 2012, 72(2):560–567.
57. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, Chretien D, de Lonlay
P, Paquis-Flucklinger V, Arakawa H, et al: Mutation of RRM2B, encoding
p53-controlled ribonucleotide reductase (p53R2), causes severe
mitochondrial DNA depletion. Nat Genet 2007, 39(6):776–780.
58. Kulawiec M, Ayyasamy V, Singh KK: p53 regulates mtDNA copy number
and mitocheckpoint pathway. J Carcinog 2009, 8:8.
59. Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, Keating MJ, Huang P:
Novel role of p53 in maintaining mitochondrial genetic stability through
interaction with DNA Pol gamma. EMBO J 2005, 24(19):3482–3492.
60. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E: The tumor suppressor
p53 down-regulates glucose transporters GLUT1 and GLUT4 gene
expression. Cancer Res 2004, 64(7):2627–2633.
61. Kawauchi K, Araki K, Tobiume K, Tanaka N: p53 regulates glucose
metabolism through an IKK-NF-kappaB pathway and inhibits cell
transformation. Nat Cell Biol 2008, 10(5):611–618.
62. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D,
Carnero A, Beach D: Glycolytic enzymes can modulate cellular life span.
Cancer Res 2005, 65(1):177–185.
63. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X: p53 regulates
biosynthesis through direct inactivation of glucose-6-phosphate
dehydrogenase. Nat Cell Biol 2011, 13(3):310–316.64. Engelman JA: Targeting PI3K signalling in cancer: opportunities,
challenges and limitations. Nat Rev Cancer 2009, 9(8):550–562.
65. Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K
pathway as an integrator of multiple inputs during tumorigenesis. Nat
Rev Cancer 2006, 6(3):184–192.
66. Feng Z: p53 Regulation of the IGF-1/AKT/mTOR Pathways and the
Endosomal Compartment. Cold Spring Harb Perspect Biol 2010, 2(2):a001057.
67. Levine AJ, Feng Z, Mak TW, You H, Jin S: Coordination and communication
between the p53 and IGF-1-AKT-TOR signal transduction pathways.
Genes Dev 2006, 20(3):267–275.
68. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak
TW: Regulation of PTEN transcription by p53. Mol Cell 2001, 8(2):317–325.
69. Feng Z, Hu W, de Stanchina E, Teresky A, Jin S, Lowe S, Levine AJ: The
regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell
and tissue specificity, and the role of these gene products in modulating
the IGF-1-AKT-mTOR pathways. Cancer Res 2007, 67(7):3043–3053.
70. Budanov AV, Karin M: p53 target genes sestrin1 and sestrin2 connect
genotoxic stress and mTOR signaling. Cell 2008, 134(3):451–460.
71. Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and
mTOR pathways in cells. Proc Natl Acad Sci USA 2005, 102(23):8204–8209.
72. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K,
Oliner JD, McKeon F, Haber DA: REDD1, a developmentally regulated
transcriptional target of p63 and p53, links p63 to regulation of reactive
oxygen species. Mol Cell 2002, 10(5):995–1005.
73. Olalla L, Gutierrez A, Jimenez AJ, Lopez-Tellez JF, Khan ZU, Perez J, Alonso
FJ, de la Rosa V, Campos-Sandoval JA, Segura JA, et al: Expression of the
scaffolding PDZ protein glutaminase-interacting protein in mammalian
brain. J Neurosci Res 2008, 86(2):281–292.
74. Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, Aaronson
SA, Lee SW: GAMT, a p53-inducible modulator of apoptosis, is critical for the
adaptive response to nutrient stress. Mol Cell 2009, 36(3):379–392.
75. Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, Xuan W, Brown-Endres L,
Tsuchihara K, Mak TW, Benchimol S: ROS-mediated p53 induction of Lpin1
regulates fatty acid oxidation in response to nutritional stress. Mol Cell
2011, 44(3):491–501.
76. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC
Jr, Kelly DP: Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/
PPARalpha regulatory pathway. Cell Metab 2006, 4(3):199–210.
77. Phan J, Reue K: Lipin, a lipodystrophy and obesity gene. Cell Metab 2005,
1(1):73–83.
78. Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y: Transcriptional activation
of the human glutathione peroxidase promoter by p53. J Biol Chem 1999,
274(17):12061–12066.
79. Yoon KA, Nakamura Y, Arakawa H: Identification of ALDH4 as a p53-inducible
gene and its protective role in cellular stresses. J Hum Genet 2004,
49(3):134–140.
80. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD: Direct
interaction between Nrf2 and p21(Cip1/WAF1) upregulates the
Nrf2-mediated antioxidant response. Mol Cell 2009, 34(6):663–673.
81. Liu G, Chen X: The ferredoxin reductase gene is regulated by the p53
family and sensitizes cells to oxidative stress-induced apoptosis.
Oncogene 2002, 21(47):7195–7204.
82. Martindale JL, Holbrook NJ: Cellular response to oxidative stress: signaling
for suicide and survival. J Cell Physiol 2002, 192(1):1–15.
83. Rivera A, Maxwell SA: The p53-induced gene-6 (proline oxidase) mediates
apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005,
280(32):29346–29354.
84. Bensaad K, Vousden KH: p53: new roles in metabolism. Trends Cell Biol
2007, 17(6):286–291.
85. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and
reduced risk of cancer in diabetic patients. BMJ 2005, 330(7503):1304–1305.
86. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B,
Thompson CB: Systemic treatment with the antidiabetic drug metformin
selectively impairs p53-deficient tumor cell growth. Cancer Res 2007,
67(14):6745–6752.
87. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L,
Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function
leads to tumour regression in vivo. Nature 2007, 445(7128):661–665.
88. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V,
Cordon-Cardo C, Lowe SW: Senescence and tumour clearance is
Liang et al. Cell & Bioscience 2013, 3:9 Page 10 of 10
http://www.cellandbioscience.com/content/3/1/9triggered by p53 restoration in murine liver carcinomas. Nature 2007,
445(7128):656–660.
89. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N,
Kammlott U, Lukacs C, Klein C, et al: In vivo activation of the p53 pathway
by small-molecule antagonists of MDM2. Science 2004, 303(5659):844–848.
90. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med 2007,
13(1):23–31.
doi:10.1186/2045-3701-3-9
Cite this article as: Liang et al.: The regulation of cellular metabolism by
tumor suppressor p53. Cell & Bioscience 2013 3:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
